NCT00645749

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: University of Wisconsin, Madison · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The hypothesis of this study is that helminth-induced immunomodulation therapy (HINT) will be safe and effective when administered orally in patients with relapsing-remitting multiple sclerosis (RRMS).

Detailed description

Phase 1 of the HINT trial was completed with enrollment of 5 subjects. HINT Phase 2 is now closed to enrollment of 15 subjects. Recruitment sites are the UW-Madison and the Marshfield Clinic.

Conditions

• Relapsing Remitting Multiple Sclerosis

Interventions

Type	Name	Description
BIOLOGICAL	Helminth ova	2500 ova per dose (liquid form)

Timeline

• Start date: 2008-07-01
• Primary completion: 2015-08-13
• Completion: 2015-08-13
• First posted: 2008-03-28
• Last updated: 2019-02-06

Locations

1 site across 1 country: United States